 BOSTON, Jan. 06, 2021 GLOBE NEWSWIRE -- Radius Health, Inc. Radius or the Company Nasdaq: RDUS today announced a definitive agreement to acquire the global development and commercialization rights to Benuvia Therapeutics Inc.s Benuvia synthetic cannabidiol oral solution RAD011. The Company plans to initiate a pivotal Phase 23 study for patients with Prader-Willi syndrome PWS in the second half of 2021 pending regulatory discussion with the U.S. Food and Drug Administration FDA. 